FDA Accepts SNY and REGN's Dupixent Re-Submitted SBLA for Urticaria

Zacks 03:30

Peering Into Regeneron Pharmaceuticals's Recent Short Interest

BenzingaNov 18 21:15

Express News | Regeneron Pharmaceuticals : Deutsche Bank Cuts Target Price to $805 From $900

BreakingsNov 18 19:59

Check Out What Whales Are Doing With REGN

BenzingaNov 15 23:35

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

BenzingaNov 15 21:44

Regeneron, Sanofi Say Resubmitted Application to Expand Dupixent Label Accepted in U.S.

Seeking AlphaNov 15 20:50